MedInCell Stock Rises 2.44% to €26.86, Marking +73% Over One Year Ahead of R&D Day
The Montpellier-based biotech's stock picks up pace mid-session, on the eve of a highly anticipated meeting with analysts. At €26.86, the stock is up 2.44% while the SBF 120 index is down 0.80% at midday. The stock ranks 6th in terms of gains in the index, indicating a performance that goes against the general trend of the Paris market.
An R&D Day Scheduled for Tomorrow, Following a Bullish Trend
MedInCell is hosting its R&D Day live on May 12, 2026. The event follows a favorable stock market sequence: the stock has gained 8.83% over the week and 73.18% over the year. Today's movement continues the breakthrough of a technical resistance that occurred on May 6 at €26.14. The price is now in uncharted territory in the short term, above the resistance zone provided at €26.52. The next financial milestone after the R&D Day is the 2026 general assembly, scheduled for September 10.
The Stock Breaks Through the Upper Bollinger Bands
At €26.86, the stock is above the upper Bollinger Band set at €26.51, which is 109% of the band, signaling potential overbuying. The RSI at 62 remains in a non-extreme zone despite the rise, leaving room before the typical overheating zone of 70. The three moving averages are aligned below the price: MM20 at €24.48 (a gap of +9.72%), MM50 at €23.04, and MM200 at €24.43. The configuration confirms the bullish orientation established since April, during which the stock moved from approximately €22.80 to over €26. The next concrete appointment for shareholders is the R&D Day on May 12, 2026.
